Innovative Pharmaceutical Biotech Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	6.2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	12.6yrs

Jüngste Management Updates

Recent updates

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Aug 12

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

Jan 05

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Feb 18

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Nov 26

Geschäftsführer

Innovative Pharmaceutical Biotech hat keinen Geschäftsführer, oder es liegen keine verfügbaren Daten vor.

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Rong Tang	Executive Director	no data	HK$548.00k	0.023% HK$ 91.1k
Yuan Xing Gao	Executive Director	no data	HK$1.36m	keine Daten
Yumin Mao	Honorary Chairman & Chief Scientific Adviser	3.8yrs	keine Daten	27.98% HK$ 110.9m
Hon Yin Poon	Financial Controller & Company Secretary	11.2yrs	keine Daten	keine Daten
Qi Dong	Sales Head of the Group	no data	keine Daten	keine Daten
Wei Yu	Joint Chairman to the Department of Innovation & Strategic Development and Advisor	no data	keine Daten	keine Daten
Jie Gu	Adviser and Joint Chairman to the Department of Innovation & Strategic Development	8.6yrs	keine Daten	keine Daten
Tak Yiu Cheng	Executive director	less than a year	keine Daten	keine Daten
Yi Xie	Chief Executive of United Gane Holdings Limited	no data	keine Daten	keine Daten
Dong Hui	General Manager of the Group and Director of CJV	no data	keine Daten	keine Daten

6.2yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von 399 ist erfahren und erfahren (durchschnittliche Amtszeit: 6 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Rong Tang	Executive Director	9.8yrs	HK$548.00k	0.023% HK$ 91.1k
Yuan Xing Gao	Executive Director	8.5yrs	HK$1.36m	keine Daten
Yumin Mao	Honorary Chairman & Chief Scientific Adviser	13.8yrs	keine Daten	27.98% HK$ 110.9m
Tak Yiu Cheng	Executive director	less than a year	keine Daten	keine Daten
Dong Hui	General Manager of the Group and Director of CJV	no data	keine Daten	keine Daten
Chung Lau	Director of CJV	no data	keine Daten	keine Daten
Weijun Chen	Independent Non-Executive Director	14.7yrs	HK$80.00k	keine Daten
Nian Jiang	Non Executive Chairman	13.6yrs	HK$60.00k	keine Daten
Yanmin Wu	Non-Executive Director	13.1yrs	HK$60.00k	keine Daten
Rongliang Wang	Independent Non-Executive Director	13.1yrs	HK$60.00k	keine Daten
Yan Xiao	Non-Executive Director	12.2yrs	HK$60.00k	keine Daten
Jinzhong Chen	Independent Non-Executive Director	3.4yrs	HK$60.00k	keine Daten

12.6yrs

Durchschnittliche Betriebszugehörigkeit

60.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 399Die Vorstandsmitglieder sind sehr erfahren ( 12.5 ).

Innovative Pharmaceutical Biotech Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2023

Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director

Less than half of directors are independent

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2022

Less than half of directors are independent

Innovative Pharmaceutical Biotech Limited Announces Executive Changes

Recent updates

Full year 2024 earnings released: EPS: HK$0.068 (vs HK$0.17 loss in FY 2023)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2024 Results on Jun 28, 2024

Innovative Pharmaceutical Biotech Limited has filed a Follow-on Equity Offering in the amount of HKD 19.95 million.

First half 2024 earnings released: EPS: HK$0.13 (vs HK$0.079 loss in 1H 2023)

New major risk - Financial position

Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023

Innovative Pharmaceutical Biotech Limited to Report First Half, 2024 Results on Nov 29, 2023

Innovative Pharmaceutical Biotech Limited (SEHK:399) entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc.

New minor risk - Share price stability

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2023

Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending 30 September 2022

Innovative Pharmaceutical Biotech Limited to Report First Half, 2023 Results on Nov 29, 2022

Less than half of directors are independent

Full year 2022 earnings released: EPS: HK$0.031 (vs HK$0.14 loss in FY 2021)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2022

Innovative Pharmaceutical Biotech Ordinary Shares to Be Deleted from Other OTC

Full year 2022 earnings released

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2022

Less than half of directors are independent

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending September 30, 2021

Full year 2021 earnings released: HK$0.14 loss per share (vs HK$0.14 loss in FY 2020)

New 90-day high: HK$0.28

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Innovative Pharmaceutical Biotech Limited Announces Executive Changes

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Innovative Pharmaceutical Biotech Limited to Report First Half, 2021 Results on Nov 27, 2020

Innovative Pharmaceutical Biotech Limited Announces Board Changes

New 90-day high: HK$0.27

New 90-day high - HK$0.26

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

Full year earnings released - HK$0.14 loss per share

Geschäftsführer

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter